Table 2.

Univariate and multivariate analyses of RFS and OS with TLS and clinicopathological characteristics in the Fudan cohort and external validation set

	Fudan cohort (n=182)				External validation set (n=125)
	Univariate analyses		Multivariate analyses		Univariate analyses		Multivariate analyses
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
RFS
AJCC8th TNM stage  (III/II/I)	2.9 (1.98–4.28)	<0.001	2.8 (1.79–4.27)	<0.001	6.1 (3.37–10.95)	<0.001	4.0 (2.05–7.73)	<0.001
WHO classification  (G3/G2/G1)	4.3 (2.45–7.71)	<0.001	2.9 (1.57–5.22)	0.001	9.8 (4.22–22.97)	<0.001	4.3 (1.70–11.01)	0.002
Vascular invasion  (positive vs negative)	1.9 (1.05–3.41)	0.033	–	–	2.2 (1.09–4.49)	0.029	–	–
Presence of TLS  (yes vs no)	0.3 (0.12–0.54)	<0.001	0.3 (0.14–0.69)	0.004	0.2 (0.06–0.45)	<0.001	0.2 (0.07–0.62)	0.005
OS
AJCC8th TNM stage  (III/II/I)	2.6 (1.42–4.69)	0.002	2.2 (1.14–4.20)	0.019	3.5 (1.87–6.48)	<0.001	2.2 (1.11–4.38)	0.024
WHO classification  (G3/G2/G1)	4.5 (2.12–9.38)	<0.001	3.0 (1.33–6.75)	0.008	10.6 (3.49–31.87)	<0.001	5.2 (1.63–16.85)	0.005
Presence of TLS  (yes vs no)	0.3 (0.11–0.64)	0.003	0.3 (0.12–0.74)	0.009	0.2 (0.06–0.44)	<0.001	0.3 (0.09–0.82)	0.020

AJCC^8th, 8th edition American Joint Committee on Cancer; G3/G2/G1, grade 3/grade 2/grade 1; OS, overall survival; RFS, recurrence-free survival; TLS, tertiary lymphoid structures; TNM, tumor-node-metastasis.